Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAKTOB (tobramycin) by Viatris (2) is clinical pharmacology: corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 7 more indications. First approved in 1996.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY: Corticoids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be…
Worked on AKTOB at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Tobramycin Injection to Prevent Infection in Open Fractures
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo